Abstract: The present invention relates to novel compositions and methods to produce 3D organ equivalents of the brain (i.e. “mini-brains”). The invention also relates to methods of using human induced pluripotent stem cells, a combination of growth and other soluble factors and gyratory shaking. Cells from healthy or diseased donors or animals can be used to allow testing different genetic backgrounds. The model can be further enhanced by using genetically modified cells, adding micro-glia or their precursors or indicator cells (e.g. with reporter genes or tracers) as well as adding endothelial cells to form a blood-brain-barrier.

Abstract: The invention provides new radiolabeled monoacylglycerol lipase (MAGL) inhibitors that are useful for medical imaging, such as positron-emission tomography (PET), single-photon emission computed tomography (SPECT) and/or autoradiography.

Abstract: The invention provides processes to manufacture substituted 1-[4-(Pyridin-2-yloxy)-cyclohexyl]-5,6-dihydro-4H-2,3,5,10b-tetraaza-benzo[e]azulenes. Also disclosed are compounds useful as intermediates in the methods of the invention.

Abstract: The invention provides processes to manufacture substituted 1-[4-(Pyridin-2-yloxy)-cyclohexyl]-5,6-dihydro-4H-2,3,5,10b-tetraaza-benzo[e]azulenes. Also disclosed are compounds useful as intermediates in the methods of the invention.

Abstract: The present invention relates to novel compositions and methods to produce 3D organ equivalents of the brain (i.e. “mini-brains”). The invention also relates to methods of using human induced pluripotent stem cells, a combination of growth and other soluble factors and gyratory shaking. Cells from healthy or diseased donors or animals can be used to allow testing different genetic backgrounds. The model can be further enhanced by using genetically modified cells, adding micro-glia or their precursors or indicator cells (e.g. with reporter genes or tracers) as well as adding endothelial cells to form a blood-brain-barrier.

Abstract: The invention provides processes to manufacture substituted 1-[4-(Pyridin-2-yloxy)-cyclohexyl]-5,6-dihydro-4H-2,3,5,10b-tetraaza-benzo[e]azulenes. Also disclosed are compounds useful as intermediates in the methods of the invention.

Abstract: The present invention provides processes to manufacture substituted 1-[4-(Pyridin-2-yloxy)-cyclohexyl]-5,6-dihydro-4H-2,3,5,10b-tetraaza-benzo[e]azulenes. Also disclosed are compounds useful as intermediates in the methods of the invention.

Abstract: The present invention relates to a compound of formula (I) wherein R1 is defined as in the description and in the claims. The compound of formula (I) can be used as radiolabeled ligand.

Abstract: Preparations containing deep-frozen blood are used for test procedures for determining blood response.

Abstract: The present invention relates to a compound of formula (I) wherein R1 is defined as in the description and in the claims. The compound of formula (I) can be used as radiolabeled ligand.

Abstract: The present invention provides processes to manufacture substituted 1-[4-(Pyridin-2-yloxy)-cyclohexyl]-5,6-dihydro-4H-2,3,5,10b-tetraaza-benzo[e]azulenes. Also disclosed are compounds useful as intermediates in the methods of the invention.

Abstract: The present invention relates to radiolabeled compounds of formula I wherein R1, R2, R3 and R4 are as defined herein.

Abstract: An ink delivery device (30) for the ink supply of an inking system (20) of a printing machine (10) with ink, includes an ink reservoir (31), a drive that is connected to the ink reservoir (31) and configured such that the ink reservoir (31) can be pressurized by the drive, and a control device for controlling the drive of the ink delivery device (30), in which the drive and the control device are configured and connected with each other such that the ink delivery device (30) can be operated based on a method, in which the method includes the following steps: initiating an ink delivery process, increasing the pressure in the ink reservoir to a target operating pressure, adjusting the pressure in the ink reservoir to an adjusted operating pressure, and terminating the ink delivery process.

Abstract: Described herein are methods for establishing the non-toxicity of a substance. For example, described herein are methods for the construction of a comprehensive database of toxicity associated pathways and methods of using such a database.

Abstract: The present invention relates to novel radiolabelled inhibitors of formula I for the Glycine 1 transporter (GlyT1), useful for the labelling and diagnostic imaging of the glycine 1 transporter functionality. wherein R1 is isopropoxy or 2,2,2-trifluoro-1-methyl-ethoxy; and R2 is a radiolabelled group CH3, wherein the radionuclide is 3H or 11C. The radiolabelled compounds of formula I may be used as PET (Positron Emission Tomography) radiotracer for the labelling and diagnostic molecular imaging of the glycine 1 transporter functionality.

Abstract: An ink delivery device (30) for the ink supply of an inking system (20) of a printing machine (10) with ink, includes an ink reservoir (31), a drive that is connected to the ink reservoir (31) and configured such that the ink reservoir (31) can be pressurized by the drive, and a control device for controlling the drive of the ink delivery device (30), in which the drive and the control device are configured and connected with each other such that the ink delivery device (30) can be operated based on a method, in which the method includes the following steps: initiating an ink delivery process, increasing the pressure in the ink reservoir to a target operating pressure, adjusting the pressure in the ink reservoir to an adjusted operating pressure, and terminating the ink delivery process.

Abstract: Testing of flowing media for microbial toxins via whole blood incubation in a flow vessel containing a separation element and assaying for mediators.

Abstract: The present invention relates to novel radiolabelled inhibitors of formula I for the Glycine 1 transporter (GlyT1), useful for the labelling and diagnostic imaging of the glycine 1 transporter functionality. wherein R1 is isopropoxy or 2,2,2-trifluoro-1-methyl-ethoxy; and R2 is a radiolabelled group CH3, wherein the radionuclide is 3H or 11C. The radiolabelled compounds of formula I may be used as PET (Positron Emission Tomography) radiotracer for the labelling and diagnostic molecular imaging of the glycine 1 transporter functionality.

Abstract: A device for supplying ink to a printing press, includes a piston pump and a hydraulic or pneumatic cylinder driving mechanism which drives the piston rod of the piston pump and the cylinder driving mechanism includes several cylinder chambers, which are separated from one another and each of which contains a driving piston, which can be acted upon with pressure.

Abstract: The present invention is concerned with a novel process for the preparation of compounds of formula (I) wherein R1 and R2 are as defined in the description and claims. The compounds of formula (I) are pharmaceutically active substances.